← All trials
NCT03150316
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 10, 2017
- Primary completion
- Jun 29, 2018
- Completion date
- Nov 19, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Chong Kun Dang PharmaceuticalLead sponsor
- Catholic University of KoreaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.